Compare
TherapeuticsMD, Inc. vs Upstream Bio, Inc. vs Camp4 Therapeutics Corp vs GeoVax Labs, Inc.
| Latest fiscal year | TherapeuticsMD, Inc. TXMD | Upstream Bio, Inc. UPB | Camp4 Therapeutics Corp CAMP | GeoVax Labs, Inc. GOVX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.02M | $2.85M | $3.50M | $2.49M |
| Revenue growth (YoY) | +71.6% | +20.4% | +436.5% | -37.1% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -145.3% | n/m | n/m | -869.3% |
| Net margin | -18.8% | n/m | n/m | -862.3% |
| Net income | -$569.0K | -$143.44M | -$80.40M | -$21.46M |
| EPS (Diluted) | -$0.05 | -$2.66 | -$2.65 | n/a |
| Operating cash flow | $2.45M | -$133.28M | -$29.55M | -$21.47M |
| Free cash flow | n/a | -$133.44M | -$29.83M | -$21.50M |
| Cash & equivalents | n/a | $101.58M | $109.52M | $3.09M |
| Total assets | $37.66M | $353.77M | $117.81M | $6.34M |
| Total liabilities | $10.78M | $14.00M | $70.10M | $2.52M |
| Shareholders' equity | $26.88M | $339.77M | $47.70M | $3.83M |
| Return on year-end equity | -2.1% | -42.2% | -168.5% | -561.2% |
| Shares outstanding | 11.57M | 54.24M | 51.90M | 1.73M |
Revenue, most recent five fiscal years
| Fiscal year | TherapeuticsMD, Inc. | Upstream Bio, Inc. | Camp4 Therapeutics Corp | GeoVax Labs, Inc. |
|---|---|---|---|---|
| Latest | $3.02M Ended 2025-12-31 | $2.85M Ended 2025-12-31 | $3.50M Ended 2025-12-31 | $2.49M Ended 2025-12-31 |
| 1 year earlier | $1.76M Ended 2024-12-31 | $2.37M Ended 2024-12-31 | $652.0K Ended 2024-12-31 | $3.95M Ended 2024-12-31 |
| 2 years earlier | $1.30M Ended 2023-12-31 | $2.38M Ended 2023-12-31 | $350.0K Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $69.96M Ended 2022-12-31 | n/a | n/a | $81.5K Ended 2022-12-31 |
| 4 years earlier | $2.57M Ended 2021-12-31 | n/a | n/a | $385.5K Ended 2021-12-31 |